These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8952859)

  • 21. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
    De Stefano V; Carobbio A; Di Lazzaro V; Guglielmelli P; Iurlo A; Finazzi MC; Rumi E; Cervantes F; Elli EM; Randi ML; Griesshammer M; Palandri F; Bonifacio M; Hernandez-Boluda JC; Cacciola R; Miroslava P; Carli G; Beggiato E; Ellis MH; Musolino C; Gaidano G; Rapezzi D; Tieghi A; Lunghi F; Loscocco GG; Cattaneo D; Cortelezzi A; Betti S; Rossi E; Finazzi G; Censori B; Cazzola M; Bellini M; Arellano-Rodrigo E; Bertozzi I; Sadjadian P; Vianelli N; Scaffidi L; Gomez M; Cacciola E; Vannucchi AM; Barbui T
    Blood Cancer J; 2018 Feb; 8(3):25. PubMed ID: 29535299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of patients with essential thrombocythemia: current concepts and perspectives.
    Briere J; Guilmin F
    Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
    Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
    Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
    Landolfi R; Di Gennaro L; Novarese L; Patrono C
    Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?
    Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):18-21. PubMed ID: 8039753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction.
    D'Andrea G; Perini F; Hasselmark L; Alecci M; Cananzi AR
    Funct Neurol; 1995; 10(2):91-8. PubMed ID: 7557557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial.
    Vetrano A; Milani M; Corsini G
    G Ital Cardiol; 1999 May; 29(5):524-8. PubMed ID: 10367219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.
    Buss DH; Stuart JJ; Lipscomb GE
    Am J Hematol; 1985 Dec; 20(4):365-72. PubMed ID: 3865532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
    Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the standard treatment in essential thrombocythemia.
    Barbui T
    Int J Hematol; 2002 Aug; 76 Suppl 2():311-7. PubMed ID: 12430943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R; Cipriani MC; Novarese L
    Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric stroke among Hong Kong Chinese subjects.
    Chung B; Wong V
    Pediatrics; 2004 Aug; 114(2):e206-12. PubMed ID: 15286258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
    Neri Serneri GG; Coccheri S; Marubini E; Violi F;
    Eur Heart J; 2004 Oct; 25(20):1845-52. PubMed ID: 15474700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
    Squizzato A; Romualdi E; Middeldorp S
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiaggregatory effects of picotamide in long-term treatment: a 2-year, double-blind placebo-controlled trial.
    Cocozza M; Milani M; Picano T; Oliviero U; Russo N; Coto V
    Vasc Med; 1997 Nov; 2(4):292-5. PubMed ID: 9575601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.